Utah Medical Products, Inc. (UTMD) AI Stock Analysis

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for healthcare applications. Its product lineup includes fetal monitoring accessories, vacuum-assisted delivery systems, and labor and delivery tools for maternal care. For neonatal and patient care, the company supplies DISPOSA-HOOD infant respiratory hoods, DELTRAN PLUS blood pressure monitoring systems, GESCO umbilical vessel catheters, DIALY-NATE disposable peritoneal dialysis sets, and PALA-NATE silicone oral protection devices. It also manufactures URI-CATH urinary drainage systems, NUTRI-CATH\NUTRI-LOK feeding devices, MYELO-NATE lumbar sampling kits, HEMO-NATE disposable filters, and catheterization procedure trays for clinical settings including neonatal intensive care units and outpatient clinics.

Revenue decreased from $49.1M in FY2021 to $38.5M in FY2025, recording a 5-year revenue CAGR of -1.8%. After peaking at $52.3M in FY2022, revenue fell 3.9% in FY2023, 18.6% in FY2024, and 5.8% in FY2025. Gross margin contracted from 63.0% in FY2021 to 51.6% in FY2025, while operating margin moved from 38.5% to 29.6%. Net income was $11.3M in FY2025 with diluted EPS of $3.48, down from $14.8M and $4.05 in FY2021. For the trailing twelve months ended June 30, 2026, revenue was $36.1M, with quarterly revenue falling 14.3% and quarterly earnings dropping 10.5% year-over-year.

As of June 30, 2026, Utah Medical Products held $87.5M in cash and short-term investments against total debt of $195,000, resulting in net cash of $87.3M. Total assets were $124.6M and shareholders' equity was $122.0M, supporting a debt-to-equity ratio of 0.00 and a current ratio of 48.62. In FY2025, operating cash flow was $14.7M and free cash flow was $14.3M. The company spent $371,000 on capital expenditures, paid $4.0M in dividends, and deployed $8.4M for share buybacks.

UTMD trades at a trailing P/E of 22.7x and a forward P/E of 13.0x, compared to the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. Its enterprise value of $151.6M reflects an EV/EBITDA of 11.9x, near the peer median of 12.0x, while its price-to-sales ratio of 6.5x stands above the peer median of 4.1x. Over the past year, the stock returned 26.4%, outperforming the S&P 500 (SPY) return of 16.8%. However, its 5-year return of -8.7% lagged the S&P 500 return of 83.0%.

Utah Medical Products pays a quarterly dividend with an annualized forward rate of $1.24 per share, representing a dividend yield of 1.66% as of October 16, 2026. The company has paid dividends for 23 consecutive years, delivering a 5-year annualized dividend growth rate of 1.7%. The payout ratio stands at 37.8%, and the last ex-dividend date was September 17, 2026.

No sell-side analyst rating counts, consensus price targets, or earnings estimate surprises are reported for Utah Medical Products. The company's next scheduled earnings release date is October 22, 2026. As of October 16, 2026, the stock closed at $74.51, which is 11.4% above its 200-day moving average and below its 52-week high of $76.89. Institutional investors hold 76.6% of shares, while insiders own 7.2%.

This page is an AI-written research summary of Utah Medical Products, Inc. (UTMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: UTMD income statement, UTMD balance sheet, UTMD key metrics, UTMD chart. See the UTMD stock overview for the latest quote and news.